Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPreventive Services & ScreeningAetna Pneumococcal Vaccines Coverage Update | Open…
    Ask Trek AI about this page
    CurrentAetnaPolicy 0037

    Pneumococcal Vaccines

    Customize your policy alerts

    Sign up for Aetna Policy 0037 alerts

    Get alerted when Policy 0037 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Aetna's clinical policy on medical necessity and coverage of pneumococcal vaccines (PCV13, PCV15, PCV20, PPSV23) for children and adults, aligned to CDC/ACIP recommendations and affecting providers who administer or bill for these vaccines.

    Policy Summary
    PayerAetna
    PolicyPneumococcal Vaccines
    Policy CodePolicy 0037
    Change TypeNo material change
    Effective DateJul 21, 1995
    Last ReviewOct 24, 2023
    Next Review DateJan 11, 2024
    Key ActionVerify prior pneumococcal vaccination and intervals before administering additional doses to determine appropriate sequencing (PCV15 → PPSV23 or PCV20 alone).
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    >=65 yrsAge threshold for universal adult recommendation
    4PCV dosing schedule for infants
    90670,90671,90677,90732Primary vaccine CPT/HCPCS codes listed
    10/24/2023Most recent policy review

    Coverage Criteria for Pneumococcal Vaccination

    Adults aged 65 years

    Recommendations and sequencing noted in cited guidance

    ALL of the following

    • CDC recommends pneumococcal vaccination for all adults 65 years or older.
    • For adults 65 years or older who have not previously received any pneumococcal vaccine: 1 dose of PCV15 or PCV20 is recommended.
    • If PCV15 is used in adults ≥65 years, it should be followed by a dose of PPSV23 at least 1 year later (minimum interval 8 weeks may be considered for certain high-risk conditions such as immunocompromise, cochlear implant, or CSF leak).
    • If PCV20 is used in adults ≥65 years, a dose of PPSV23 is not indicated.
    • For adults ≥65 years who have only received PPSV23 previously, a single dose of PCV15 or PCV20 is recommended at least 1 year after the most recent PPSV23 dose.
    • For adults ≥65 years who have only received PCV13 previously, give PPSV23 as previously recommended; the incremental public health benefit of providing PCV15 or PCV20 after PCV13 (with or without PPSV23) has not been established.
    • If PCV13 was given but PPSV23 series is incomplete and PPSV23 is unavailable, one dose of PCV20 may be used to complete the pneumococcal vaccination series.

    Evidence summaries

    Clinical-effectiveness statements extracted from the background section

    ALL of the following

    • A randomized placebo-controlled trial of PCV13 in ~84,500 adults aged ≥65 years showed no reduction in overall mortality or overall incidence of community-acquired pneumonia over an average 4-year follow-up; the number needed to vaccinate to prevent one case of vaccine-type pneumococcal pneumonia was approximately 1,000 (No authors listed, 2016).
    • Evidence for clinical protection against invasive pneumococcal disease (IPD) in solid organ transplant recipients and other immunocompromised populations is limited to immunogenicity and small trials; transplant recipients mount serologic responses but responses are generally lower than healthy controls and clinical efficacy data are lacking (Dendle et al., 2018).
    • Studies in rheumatoid arthritis patients indicate that certain immunosuppressive therapies (e.g., methotrexate, rituximab) reduce humoral responses to pneumococcal vaccination, whereas anti-TNF agents have less consistent impact (Hua et al., 2014).
    • For PPSV23, revaccination in immunocompetent persons previously vaccinated is generally not recommended; revaccination may be considered for selected high-risk individuals or immunocompromised patients due to waning immunity, but routine revaccination is not supported by high-quality evidence (PPSV23 background, Merck, 2021b; Chang et al., 2007).

    Billing and Coding

    Covered CPT/HCPCS/ICD-10 codes (when selection criteria met)mixedCovered
    90670Pneumococcal conjugate vaccine, 13 valent, for intramuscular use.
    90671Pneumococcal conjugate vaccine, 15 valent (PCV15), for intramuscular use.
    90677Pneumococcal conjugate vaccine, 20 valent (PCV20), for intramuscular use.
    90732Pneumococcal polysaccharide vaccine, 23-valent, adult or immunosuppressed patient dosage, when administered to individuals 2 years or older, for subcutaneous or intramuscular use.
    90460Immunization administration through 18 years of age via any route of administration, with counseling by physician or other qualified health care professional; first or only component of each vaccine or toxoid administered.
    90461Each additional vaccine or toxoid component administered (List separately in addition to code for primary procedure).
    90471Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections); 1 vaccine (single or combination vaccine/toxoid).
    90472Each additional vaccine (single or combination vaccine/toxoid) (List separately in addition to code for primary procedure).
    G0009Administration of pneumococcal vaccine.
    G0310Immunization counseling by a physician or other qualified health care professional when the vaccine(s) is not administered on the same date of service, 5 to 15 mins time (used for Medicaid billing purposes).
    1–10 of 14
    1/2

    Provider Actions, Billing, and Documentation

    Prior Authorization

    Verify Benefits / Prior Authorization

    Check member benefits and verify any prior authorization requirements with Aetna before administering pneumococcal vaccines. This Clinical Policy Bulletin assists with administering benefits but does not itself specify plan-level prior authorization rules; providers are responsible for benefit verification.

    • Providers must verify prior authorization and coverage with the member's plan before vaccination.
    Denial Risk

    Experimental / Investigational Exclusion

    Pneumococcal vaccines (PCV13, PCV15, PCV20, PPSV23) are considered experimental/investigational and may be denied when administered to groups not listed as medically necessary in Section I. Claims for populations outside the specified recommendations may be denied as not medically necessary.

    • Vaccination outside listed groups is considered experimental/investigational by Aetna and may not be covered.

    Background and Epidemiology

    Streptococcus pneumoniae is a major cause of morbidity and mortality worldwide, responsible for clinical syndromes including pneumonia, bacteremia, and meningitis. Invasive disease rates are highest among young children and adults aged ≥65 years and are increased in persons with certain comorbid conditions; ACIP recommendations guide use of pneumococcal conjugate and polysaccharide vaccines to reduce these outcomes.

    Definitions and Vaccine Descriptions

    inv-31: Pneumococcal vaccines — Two types available in the U.S.: PCV (PCV13, PCV15, PCV20) and PPSV23
    Vaccine types available in U.S.Two types: pneumococcal conjugate vaccines (PCV13, PCV15, PCV20) and pneumococcal polysaccharide vaccine (PPSV23).
    PCV examplesPCV13 (Prevnar 13), PCV15 (Vaxneuvance), PCV20 (Prevnar 20).
    PPSV examplePPSV23 (Pneumovax 23) — polysaccharide vaccine covering 23 serotypes.
    inv-32: PPSV23 / PCV — PPSV23 (Pneumovax 23) is a 23-valent polysaccharide vaccine; PCV13/15/20 described
    PPSV23 descriptionPneumovax 23 is a 23-valent purified capsular polysaccharide vaccine (PPSV23) indicated for persons ≥50 years and persons ≥2 years at increased risk; not approved for children <2 years.
    PPSV23 serotype coverage
    Policy Summary
    PayerAetna
    PolicyPneumococcal Vaccines
    Policy CodePolicy 0037
    Change TypeNo material change
    Effective DateJul 21, 1995
    Last ReviewOct 24, 2023
    Next Review DateJan 11, 2024
    Key ActionVerify prior pneumococcal vaccination and intervals before administering additional doses to determine appropriate sequencing (PCV15 → PPSV23 or PCV20 alone).
    SourceLink
    On This Page
    Coverage Criteria for Pneumococcal VaccinationBilling and CodingProvider Actions, Billing, and DocumentationBackground and EpidemiologyDefinitions and Vaccine Descriptions
  1. There is insufficient evidence from randomized trials that routine pneumococcal vaccination reduces morbidity in bronchiectasis or cystic fibrosis populations; no RCTs were identified for CF and evidence is inadequate to draw firm conclusions (Cochrane reviews; Burgess and Southern, 2014; Chang et al., 2007).
  2. PCV15 (Vaxneuvance) was noninferior to PCV13 in immunogenicity trials in infants, children, and adolescents and elicited comparable or higher responses for shared and unique serotypes; some diminished responses are seen in individuals with altered immunocompetence (Merk, 2022).
  3. Prevnar 20 (PCV20) is licensed for adults as a single dose; effectiveness for prevention of pneumonia in individuals younger than 18 years has not been established in clinical trials (Wyeth Pharmaceuticals, 2023).
  4. Denial Risk

    Contraindications for Prevnar 20

    Prevnar 20 (PCV20) is contraindicated in individuals with a known allergy to any component of the vaccine or to diphtheria toxoid. Consult the vaccine prescribing information for additional warnings and precautions (e.g., apnea risk in certain premature infants).

    • Contraindication: Allergy to any component of Prevnar 20 or to diphtheria toxoid.
    • Review full prescribing information for pregnancy, lactation, and other warnings.
    Billing Rule

    Coding and Documentation

    Use the listed CPT, HCPCS, and ICD-10 codes when billing for pneumococcal vaccination encounters and administration. Document the encounter with ICD-10 code Z23 and include appropriate vaccine CPT/HCPCS codes when selection criteria are met.

    • Covered CPT codes when selection criteria met: 90670, 90671, 90677, 90732.
    • Administration and counseling codes: 90460–90472 (as applicable) and 90471–90472; HCPCS administration code G0009.
    • ICD-10 code for encounter: Z23.
    Documentation Required

    Document Prior Vaccination and Indication

    When administering pneumococcal conjugate vaccines to adults and children, document prior pneumococcal vaccination history and the clinical indication (age, risk conditions, immunocompromising status) that supports vaccine selection and sequencing per ACIP guidance.

    • Document prior vaccine history (PCV13, PCV15, PCV20, PPSV23) and dates.
    • Document patient risk status or indication for vaccination.
    Documentation Required

    Elective Splenectomy — Timing and Documentation

    For elective splenectomy, document administration of pneumococcal, meningococcal, and Hib vaccines at least 14 days prior to surgery. If preoperative administration is not possible, document vaccination on or after postoperative day 14.

    • Administer and document pneumococcal, meningococcal, and Hib vaccines ≥14 days before elective splenectomy when possible.
    • If not given preoperatively, document administration on or after postoperative day 14.
    Note

    Vaccine Sequencing and Intervals

    Follow ACIP sequencing guidance when selecting vaccines: PCV15 should be followed by PPSV23 (typically ≥1 year later; minimum 8 weeks in certain high‑risk or immunocompromised adults). PCV20 may be used alone without subsequent PPSV23. If PCV13 is used in shared clinical decision‑making for adults ≥65, administer PCV13 before PPSV23 and observe recommended intervals.

    • If PCV15 is administered, give PPSV23 at least 1 year later (minimum 8 weeks for certain high‑risk/immunocompromised adults).
    • If PCV20 is administered, PPSV23 is not routinely indicated.
    • When PCV13 is used in adults ≥65 by shared decision‑making, give PCV13 before PPSV23 and maintain the recommended intervals.
    Step Therapy

    Step‑Therapy

    No step‑therapy requirements are described in this Clinical Policy Bulletin. Providers should follow ACIP recommendations and plan coverage rules; verify any utilization management requirements with the payer.

    • There are no step‑therapy requirements specified in this policy.
    • Verify any plan-specific utilization management policies with Aetna.
    Contains antigens for 23 S. pneumoniae serotypes (1,2,3,4,5,6B,7F,8,9N,9V,10A,11A,12F,14,15B,17F,18C,19F,19A,20,22F,23F,33F).
    PCV general notePCVs are conjugate vaccines (PCV13, PCV15, PCV20) with varying serotype coverage and age indications per FDA labeling.
    inv-33: PCV15 (Vaxneuvance) — 15-valent conjugate vaccine; noninferiority and immunogenicity findings referenced
    Vaccine identityPCV15 (Vaxneuvance) is a 15-valent pneumococcal conjugate vaccine supplied as a 0.5 mL single-dose prefilled syringe for intramuscular injection and approved for individuals 6 weeks of age and older.
    Immunogenicity findingsPCV15 was found noninferior to Prevnar 13 in infants, children and adolescents; higher immune responses were observed for unique serotypes 22F and 33F in studies.
    Immune response cautionSome individuals with altered immunocompetence may have reduced immune responses to Vaxneuvance.
    inv-34: PCV20 (Prevnar 20) — 20-valent conjugate vaccine contains PCV13 serotypes plus seven additional serotypes
    Vaccine identityPCV20 (Prevnar 20) is a 20-valent pneumococcal conjugate vaccine supplied as a 0.5 mL single-dose prefilled syringe for intramuscular injection.
    Serotype compositionContains the 13 serotypes in PCV13 plus seven additional serotypes: 8, 10A, 11A, 12F, 15B, 22F, and 33F.
    Approval basisFDA approvals for adults were supported by Phase 1–3 trials (>6,000 adult subjects); pediatric approval based on phase 2/3 trials; some adult pneumonia indications approved under accelerated approval based on OPA immune responses.
    inv-35: PCV7 — 7-valent pneumococcal conjugate vaccine (CRM197-conjugated)
    Vaccine identityPCV7 is a 7-valent pneumococcal conjugate vaccine (CRM197-conjugated) used historically with modest benefit for AOM prevention in healthy infants.
    AOM evidencePCV7 showed modest beneficial effects in healthy infants with low baseline risk of acute otitis media; no benefit observed when given to high-risk infants after early infancy or to older children with prior AOM.
    inv-36: PCV13 / PCV15 / PCV20 — 13-, 15-, and 20-valent conjugate vaccines referenced as licensed/approved formulations
    Licensed conjugate vaccinesPCV13 (Prevnar 13), PCV15 (Vaxneuvance), and PCV20 (Prevnar 20) are licensed/approved conjugate vaccine formulations in the U.S. with specified age and indication labeling.
    PCV13 indicationsPrevnar 13 is FDA‑approved for children 6 weeks through 17 years and for adults 18 years and older for prevention of invasive disease and (in adults) pneumonia for listed serotypes.
    PCV15 and PCV20 approvalsPCV15 approved for individuals ≥6 weeks for prevention of invasive disease for listed serotypes; PCV20 approved for individuals ≥6 weeks for IPD and for adults ≥18 for pneumonia with some indications under accelerated approval.